AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 10, 2026, 12:56 PM ET B. Riley Securities lifts Eton price target to $81 from $70, keeps Buy rating AI-generated summary · Source: press report
$ETONSpecialty medicines and rare diseasesDated financialsExecution and funding risk

ETON Stock Hub: Eton Pharmaceuticals News, Operations and Capital

HEMANGEOL has lifted sales and IMPAVIDO is available. The next test is whether collections and product margins can finance development, license payments and the approaching debt installments. On November 5, Eton reported record third-quarter revenue of $57.9 million, raised its 2026 revenue guidance to more than $175 million and released preliminary ET-700 pilot results. Historical financial and clinical observations retain the dates shown below.

Last updated: November 8, 2026Financial period: September 30, 2026 (results release); earlier figures retain their datesCurrency: U.S. dollars unless stated otherwiseResearch report: November 8, 2026
Full research report · PDF
Eton Pharmaceuticals ($ETON), research as of November 8, 2026
14 pages. The report examines HEMANGEOL and IMPAVIDO within Eton’s specialty-medicine portfolio and commercial infrastructure. It follows acquisition obligations, product economics, cash conversion and development milestones, setting revenue growth against the financing and execution needed to sustain it, and incorporates the third-quarter 2026 results reported on November 5, 2026. This is dated research; the hub follows later developments. For personal use only: redistribution prohibited.
Get the report (PDF)
Next scheduled investor event
November 16, 2026 · 10:00 a.m. ET

Presentation at the Jefferies Global Healthcare Conference in London (10:00–10:25 a.m. ET), with a webcast. Company announcement

Third-quarter results were published on November 5, 2026 and discussed on a 4:30 p.m. ET call (Q3 2026 results). $3 million quarterly principal installments begin in November 2026; after a $5 million prepayment, the final December 2027 payment is $7 million (Q3 Form 10-Q). The company reports FDA goal dates of March 29, 2027 for the LIBERVANT application and May 28, 2027 for the KHINDIVI label expansion, and targets an AMGLIDIA (glyburide oral suspension) NDA near the end of 2026 or in early 2027; these are review dates and targets, not approvals.
Eton Pharmaceuticals ETON daily stock chart
Daily chart $ETON. The chart link is an affiliate link. Interactive chart with bull and bear scenarios on JC Just Charts →

ETON stock at a glance

Chart analysis · JC
Technical chart analysis of $ETON with bull and bear scenarios on JC Just Charts.
CASH AND EQUIVALENTS
$55.628M
September 30, 2026; $26.845M at June 30 · Source
OPERATING CASH FLOW · 9M
$49.901M
Nine months ended September 30, 2026 · Source
LOAN PRINCIPAL
$22M
September 30, 2026, after a $5M prepayment; $27M at June 30; maturity December 2027 · Source
QUARTERLY REVENUE
$57.9M
Quarter ended September 30, 2026; +158% from $22.5M · Source
ANNUAL REVENUE OUTLOOK
>$175M
2026 guidance raised November 5, 2026 from >$145M; adjusted EBITDA margin of at least 40% · Source
SHARES OUTSTANDING
28.828M
September 30, 2026; issuer count rounded · Source
SHORT FLOAT
5.68%
Data as of October 2, 2026 ·

Where Eton Pharmaceuticals stands now

HEMANGEOL has lifted sales and IMPAVIDO is available. The next test is whether collections and product margins can finance development, license payments and the approaching debt installments. Source Source

On November 2, 2026, Eton announced ET-900, a program evaluating mecasermin (recombinant IGF-1, the active ingredient in INCRELEX) for infantile and epileptic spasms, together with a license agreement with Baylor College of Medicine covering patent rights for the use of IGF-1 in spasms; Eton retains commercial rights. An IND has been submitted to the FDA for an investigator-sponsored Phase 2 study, sponsored by the University of Chicago, expected to enroll up to 20 patients aged 2–18 years at three sites, with initial enrollment and dosing targeted for the first quarter of 2027. The supporting evidence is preclinical: in an animal model, IGF-1 reduced daily spasm counts by approximately 50% and eliminated spasms in 20% of treated animals. Mecasermin is not FDA-approved for infantile or epileptic spasms, and the release does not state the financial terms of the license. Source: SEC

On November 5, 2026, Eton reported third-quarter revenue of $57.9 million, up 158% from $22.5 million, with adjusted EBITDA of $28.5 million, or 49% of revenue (non-GAAP, as reported by the company). Net income was $35.2 million, or $1.06 per diluted share, including an income tax benefit from releasing the valuation allowance on its federal and part of its state deferred tax assets; non-GAAP net income was $16.5 million, or $0.50 per diluted share. Cash and cash equivalents were $55.6 million at September 30. Eton raised its 2026 guidance to more than $175 million of revenue, from more than $145 million, and to an adjusted EBITDA margin of at least 40%, from at least 35%; these are company forecasts. The company also reported FDA goal dates of March 29, 2027 for LIBERVANT, with a planned April 2027 launch, and May 28, 2027 for the KHINDIVI label expansion to children under five. Q3 2026 results

The same day, Eton released preliminary results from a four-week, randomized, double-blind, placebo-controlled pilot study of ET-700, its investigational extended-release zinc acetate for Wilson disease, in 36 healthy participants. Treatment-related adverse events occurred in 1 of 12 participants on ET-700, 8 of 12 on GALZIN and 3 of 12 on placebo, with no serious adverse events. In the prespecified per-protocol analysis of 29 participants, hepatic copper uptake decreased 12% with ET-700 and 46% with GALZIN and increased 11% with placebo; in the supportive analysis of 35 participants, GALZIN showed a greater effect than ET-700 (p=0.023). Eton plans to test faster-release formulations in additional study arms in 2027. The company notes that the findings are preliminary and are not proof of clinical efficacy in patients with Wilson disease. ET-700 pilot results

The main constraint. The adverse scenario would arise if acquired sales carry weaker margins, patient conversion fails to become sustained use, or receivables absorb cash while development and debt payments increase. International INCRELEX sales already depressed the second-quarter 2026 adjusted gross margin, according to the August 13 release. IMPAVIDO also carries a substantial revenue-sharing obligation. Revenue growth can therefore coexist with a deterioration in the cash retained from each dollar sold. Source Source

The constructive case

The favorable scenario would develop if HEMANGEOL’s patient transition supports recurring demand, the September 28 IMPAVIDO relaunch adds profitable sales, and the established endocrinology products continue growing without an equivalent increase in overhead. The August 13 outlook already incorporates the $3 million ASN-001 license expense and a possible $4 million ALKINDI SPRINKLE commercial milestone. Meeting the higher guidance while absorbing those items would be more persuasive than a revenue beat financed by stretching payables or selling additional equity. Source Source

The cautious case

The adverse scenario would arise if acquired sales carry weaker margins, patient conversion fails to become sustained use, or receivables absorb cash while development and debt payments increase. International INCRELEX sales already depressed the second-quarter 2026 adjusted gross margin, according to the August 13 release. IMPAVIDO also carries a substantial revenue-sharing obligation. Revenue growth can therefore coexist with a deterioration in the cash retained from each dollar sold. Source Source

Latest Eton Pharmaceuticals news

Nov 10, 2026

B. Riley Securities lifts Eton price target to $81 from $70, keeps Buy rating

B. Riley Securities raised its price target on Eton Pharmaceuticals to $81 from $70. The firm kept its Buy rating. Analyst action reported by the press; it is the bank's view, not Merlintrader's.

Nov 6, 2026

Canaccord Genuity increases Eton Pharmaceuticals price target to $80

Canaccord Genuity raised its price target on Eton Pharmaceuticals to $80 from $68. The firm kept its Buy rating on the stock. Analyst action reported by the press; it is the bank's view, not Merlintrader's.

Nov 6, 2026

H.C. Wainwright lifts Eton Pharmaceuticals price target to $80 from $70

H.C. Wainwright raised its price target on Eton Pharmaceuticals to $80 from $70. The firm kept its Buy rating on the stock. Analyst action reported by the press; it is the bank's view, not Merlintrader's.

Nov 5, 2026

Eton Pharmaceuticals reports third quarter 2026 financial results

Eton reported third quarter 2026 revenue of $57.9 million, compared to $22.5 million in the prior-year period, an increase of 158%. GAAP fully diluted EPS was $1.06 and non-GAAP fully diluted EPS was $0.50; Adjusted EBITDA was $28.5 million, or 49% of revenue. The company raised 2026 revenue guidance to more than $175 million from more than $145 million, and Adjusted EBITDA margin guidance to more than 40% from more than 35%.

Nov 5, 2026

Eton announces preliminary ET-700 pilot study results on copper absorption, tolerability

Eton Pharmaceuticals reported preliminary results from a randomized, double-blind, placebo-controlled pilot study of ET-700, its investigational extended-release zinc acetate formulation for Wilson disease. Treatment-related adverse events occurred in 1 of 12 ET-700 participants versus 8 of 12 GALZIN participants. Hepatic copper uptake decreased 12% with ET-700 and 46% with GALZIN, compared with an 11% increase with placebo. The company plans additional study arms in 2027 evaluating faster-release formulations.

Nov 4, 2026

Eton Pharmaceuticals to present at 2026 Jefferies Global Healthcare Conference in London

Eton Pharmaceuticals said members of its executive leadership team will present at the 2026 Jefferies Global Healthcare Conference in London from November 16-19, 2026. The presentation is scheduled for Monday, November 16th, with a webcast available. Eton currently has twelve rare disease products and six additional late-stage product candidates.

ETON stock catalysts: operating and financial milestones

  • November 5, 2026 — Q3 results: revenue of $57.9 million, 2026 revenue guidance raised to more than $175 million; preliminary ET-700 pilot results released; call held at 4:30 p.m. ET. Completed
  • November 16, 2026 — Presentation at the Jefferies Global Healthcare Conference in London, 10:00–10:25 a.m. ET (3:00–3:25 p.m. GMT), with a webcast. Company-announced investor event
  • November 2026 — Scheduled $3 million quarterly loan principal installment. Dated contractual obligation
  • Year-end 2026 / early 2027 — AMGLIDIA (glyburide oral suspension) NDA submission, after the completed bioavailability study. Company target
  • January 2027 — First participant expected in the ASN-001 bioavailability study; NDA submission anticipated in 2027. Company target
  • Q1 2027 — Targeted initial enrollment and dosing in the investigator-sponsored Phase 2 study of ET-900 (mecasermin) in refractory epileptic spasms; the IND has been submitted. Company target
  • March 29, 2027 — FDA goal date for the LIBERVANT application adding ages 6 to 11; launch planned for April 2027. Regulatory date reported by the company
  • May 28, 2027 — FDA goal date for the KHINDIVI label expansion to children under five. Regulatory date reported by the company
  • 2027 — Additional ET-700 study arms testing faster-release formulations. Company plan

November 5, 2026 results November 5, 2026 ET-700 disclosure November 4, 2026 disclosure November 2, 2026 disclosure October 14, 2026 disclosure October 14, 2026 disclosure October 6, 2026 disclosure

Scenarios: can a larger portfolio produce more cash per share?

Eton’s favorable case requires its expanded rare disease portfolio to sustain growth while paying for development, acquired rights and debt service. Product revenue reached $37.589 million in the quarter ended June 30, 2026, and operating cash flow was positive $14.660 million for the first half. Those are established operating results. Management’s August 13 forecast of more than $145 million in annual revenue and an adjusted EBITDA margin of at least 35% still requires a stronger second half and is a forecast. On November 5, 2026, after third-quarter revenue of $57.9 million, management raised that forecast to more than $175 million with an adjusted EBITDA margin of at least 40%; nine-month operating cash flow was $49.901 million. Source The relevant question is how much of that expansion remains available to shareholders after the costs of obtaining and supporting the products. Source Source The favorable scenario would develop if HEMANGEOL’s patient transition supports recurring demand, the September 28 IMPAVIDO relaunch adds profitable sales, and the established endocrinology products continue growing without an equivalent increase in overhead. The August 13 outlook already incorporates the $3 million ASN-001 license expense and a possible $4 million ALKINDI SPRINKLE commercial milestone. Meeting the higher guidance while absorbing those items would be more persuasive than a revenue beat financed by stretching payables or selling additional equity. Source Source

What Would Falsify This Reading

The constructive reading depends on a larger commercial portfolio producing sustainable cash after partner payments and development. These observations would weaken it. These are observations that would weaken the interpretation, not forecasts of inevitable events.

Merlintrader Health Score · $ETON

3.80out of 5
Financial resources · 30%4.0

Cash rose to $55.628 million at September 30, 2026 from $26.845 million at June 30, with nine-month operating cash flow of $49.901 million after $18.225 million of product-license purchases. Loan principal was $22 million at September 30, 2026, down from $27 million at June 30 after a $5 million prepayment of the final installment, with $3 million quarterly installments restarting in November. Source Source

Catalysts · 30%4.0

The company reports FDA goal dates of March 29, 2027 for LIBERVANT and May 28, 2027 for the KHINDIVI label expansion, with an AMGLIDIA NDA targeted near year-end 2026 or early 2027. ET-700 pilot data showed better tolerability but weaker copper-absorption inhibition than GALZIN. Source Source Source Source Source

Capital allocation · 20%3.0

The September 30, 2026 accounts show substantial reinvestment, royalties and existing equity awards. Growth needs to improve retained cash and diluted earnings, not only sales. Source

Trading liquidity · 10%3.5

Market data as of October 2, 2026 report a 27.18 million float and a 5.68% short float. Positioning may influence reactions without establishing fair value.

Operating execution · 10%4.5

Q3 2026 revenue rose 158% to a record $57.9 million and 2026 revenue guidance was raised to more than $175 million, after Q2 revenue had nearly doubled. Those are commercial achievements, separate from future approvals. Source Source

Assessed November 5, 2026, after the Q3 2026 results and the ET-700 pilot data: financial resources raised from 3.5 to 4.0, catalysts from 3.5 to 4.0 and operating execution from 4.0 to 4.5. Reviewed November 8, 2026 with the Q3 Form 10-Q debt schedule; scores unchanged. Weighted calculation: 4.0×30% + 4.0×30% + 3.0×20% + 3.5×10% + 4.5×10% = 3.80. This describes financial and operational robustness over twelve to eighteen months, not an investment recommendation.

Red flags

  • Historical cash is not a current cash balance; subsequent spending and financing matter.
  • Company milestones remain conditional where explicitly identified as plans or targets.
  • The adverse scenario would arise if acquired sales carry weaker margins, patient conversion fails to become sustained use, or receivables absorb cash while development and debt payments increase. International INCRELEX sales already depressed the second-quarter 2026 adjusted gross margin, according to the August 13 release. IMPAVIDO also carries a substantial revenue-sharing obligation. Revenue growth can therefore coexist with a deterioration in the cash retained from each dollar sold. Source Source
  • ET-700 inhibited copper absorption less than GALZIN in the preliminary pilot study (12% versus 46% decrease in hepatic copper uptake in the per-protocol analysis); faster-release formulations are still to be tested in 2027. Source
  • Q3 2026 net income of $35.2 million includes a one-time income tax benefit; non-GAAP net income was $16.5 million. Source
  • ET-900 is at the IND stage: the supporting evidence is preclinical, the Phase 2 study is investigator-sponsored and not yet started, and the license terms are not disclosed. Source

ETON Stock FAQ: Eton Pharmaceuticals Questions Answered

What is the next ETON stock catalyst?

After reporting Q3 2026 results on November 5, 2026, Eton executives are scheduled to present at the Jefferies Global Healthcare Conference in London on November 16, from 10:00 to 10:25 a.m. ET. The company targets an AMGLIDIA (glyburide oral suspension) NDA near the end of 2026 or in early 2027 and initial ET-900 enrollment and dosing in Q1 2027, and reports FDA goal dates of March 29, 2027 for LIBERVANT and May 28, 2027 for the KHINDIVI label expansion. Development windows are company targets. Q3 2026 results and timelines. AMGLIDIA filing plan. November 2 ET-900 study timetable. November 4 Jefferies presentation announcement.

Is Eton’s KHINDIVI approved for children under five?

Eton’s July 29, 2026 update says KHINDIVI is approved for patients aged five and above, with an expansion application submitted for younger children. The new formulation demonstrated bioequivalence to ALKINDI SPRINKLE. On November 5, 2026, Eton said the FDA had accepted the Prior Approval Supplement for review with a May 28, 2027 goal date; the submission itself does not approve the younger age group. KHINDIVI review date. Current indication and submitted expansion.

How much cash does Eton have, and is it burning cash?

Eton had $55.628 million of cash and equivalents at September 30, 2026, up from $26.845 million at June 30, and generated $49.901 million of operating cash in the first nine months; product-license purchases used $18.225 million and debt repayments $8 million. September 30 cash and cash flows. Loan principal was $22 million at September 30, 2026, after a $5 million prepayment of the final installment during the third quarter; $3 million quarterly principal payments begin in November 2026 and the final payment due in December 2027 is now $7 million, according to the Q3 Form 10-Q. Q3 Form 10-Q: SWK debt schedule.

How many ETON shares are outstanding, and can Eton issue more?

Eton had 28,842,215 common shares outstanding on November 2, 2026, according to its Q3 Form 10-Q, versus 28,583,135 on August 11. Its accounts describe stock options and employee equity arrangements that can increase the share base; option exercises provided $5.823 million of financing cash in the first nine months of 2026. Q3 Form 10-Q: share count, equity awards and financing cash flows.

When did Eton Pharmaceuticals report Q3 2026 earnings?

Eton Pharmaceuticals reported Q3 2026 financial results on November 5, 2026 and hosted a conference call and webcast at 4:30 p.m. Eastern Time. Revenue was $57.9 million and 2026 revenue guidance was raised to more than $175 million. As of November 5, the next reporting date had not been announced. Q3 2026 results.

What does Eton Pharmaceuticals do?

Eton Pharmaceuticals develops and commercializes treatments for rare diseases, using a specialty-medicine portfolio that includes endocrine and pediatric products. HEMANGEOL treats infantile hemangioma, and Eton announced U.S. commercial availability of the already approved IMPAVIDO on September 28, 2026. Its acquired products and development programs carry separate partner-payment and execution obligations. Company portfolio and HEMANGEOL business. Completed IMPAVIDO commercial launch.

Has Eton submitted ASN-001 to the FDA?

Not yet. Eton’s August 5, 2026 announcement targeted an ASN-001 NDA in H2 2027 after a bioavailability bridging study, with potential approval and launch in 2028. On November 5, 2026, Eton said the bioavailability study had been initiated, with the first participant expected to be dosed in January 2027, and that it anticipates submitting the NDA in 2027. ASN-001 update. The topical infantile-hemangioma program follows a completed clinical study and would use Eton’s existing pediatric dermatology commercial infrastructure. ASN-001 bridging study and regulatory targets.

What is Eton’s ET-900 program for infantile spasms?

Eton’s November 2, 2026 announcement introduces ET-900, mecasermin for infantile and epileptic spasms, with an IND submitted for an investigator-sponsored Phase 2 study. University of Chicago sponsorship covers up to 20 patients aged 2–18 at three sites, with initial dosing targeted for Q1 2027. Eton retains commercial rights under the Baylor license. Supporting animal findings are preclinical, and mecasermin is not approved for these spasms. ET-900 license, submitted IND and study plan.

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent educational research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $ETON or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.

Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.